On Nov 05, major Wall Street analysts update their ratings for $Owens & Minor (OMI.US)$, with price targets ranging from $12.5 to $18.5.
BofA Securities analyst Allen Lutz maintains with a sell rating, and adjusts the target price from $16 to $12.5.
Citi analyst Daniel Grosslight maintains with a buy rating, and sets the target price at $18.5.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $18 to $14.
Baird analyst Eric Coldwell maintains with a hold rating, and adjusts the target price from $19 to $14.
Leerink Partners analyst Michael Cherny maintains with a hold rating, and adjusts the target price from $17 to $14.
Furthermore, according to the comprehensive report, the opinions of $Owens & Minor (OMI.US)$'s main analysts recently are as follows:
The company's Q3 results demonstrated a varied performance, with revenue matching expectations but segment profitability showing fluctuations. The company is persistently addressing its eligibility backlog which arose following the Change hack.
The company's third-quarter performance exceeded expectations but was counterbalanced by a reduction in profitability forecasts for fiscal 2024 and a negative free cash flow projection.
The company's recent quarter results showcased robust EBIT growth in its Patient Direct sector, which was somewhat offset by underperformance in Product & Health Services. The standout feature of the quarter was the notable operating margin in Patient Direct. However, there's growing concern regarding margin pressures within medical distribution, raising further questions about competitive movements in that area. This leads to a more cautious stance concerning the margin outlook leading up to 2025.
The assessment of Owens & Minor's third quarter performance indicated it met expectations with minimal surprises, and the initial negative reaction in the stock market was deemed excessive. The fourth quarter is anticipated to face challenges due to the residual impacts of hurricane activity on the company's PHS segment, which is likely to be somewhat balanced by a more robust Patient Direct segment. Additionally, cash flow is projected to experience a sequential improvement.
Here are the latest investment ratings and price targets for $Owens & Minor (OMI.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月5日，多家华尔街大行更新了$欧麦斯-麦能医疗 (OMI.US)$的评级，目标价介于12.5美元至18.5美元。
美银证券分析师Allen Lutz维持卖出评级，并将目标价从16美元下调至12.5美元。
花旗分析师Daniel Grosslight维持买入评级，目标价18.5美元。
巴克莱银行分析师Stephanie Davis维持持有评级，并将目标价从18美元下调至14美元。
贝雅分析师Eric Coldwell维持持有评级，并将目标价从19美元下调至14美元。
Leerink Partners分析师Michael Cherny维持持有评级，并将目标价从17美元下调至14美元。
此外，综合报道，$欧麦斯-麦能医疗 (OMI.US)$近期主要分析师观点如下：
公司的第三季度业绩表现多样，营业收入符合预期，但板块利润出现波动。公司正在坚定地解决由Change黑客事件引发的资格积压问题。
公司第三季度的表现超出了预期，但与之相抵触的是对2024财年盈利预测的下调以及负面的自由现金流预测。
公司最近一个季度的业绩展示了患者直销板块EBIt增长强劲，但产品与健康服务板块表现不佳。该季度的一大亮点是患者直销板块可观的营业利润率。然而，医疗分配领域的利润压力引起了日益关注，进一步引发了对该领域竞争动向的疑问。这导致对2025年前景更为谨慎。
对欧文与小公司第三季度业绩的评估表明，它符合预期，没有太多惊喜，股市最初的负面反应被认为过度。第四季度预计将面临挑战，因飓风活动对公司PHS板块的残留影响，这可能在一定程度上被更强劲的患者直销板块所平衡。此外，现金流预计将出现顺序改善。
以下为今日5位分析师对$欧麦斯-麦能医疗 (OMI.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
